Skip to main content

Table 1 Clinical characteristics of HBsAg-positive and -negative patients with diffuse large B-cell lymphoma

From: Clinicopathological and prognostic features of hepatitis B virus-associated diffuse large B-cell lymphoma: a single-center retrospective study in China

Factors HBsAg-positive patients (n = 127) HBsAg-negative patients (n = 293) P value
No % No %
Age > 60 22 17.3 97 33.1 0.001*
Gender      0.116*
 Male 79 62.2 158 53.9  
 Female 48 37.8 135 46.1  
Bulky mass (≥ 7.5 cm) 22 17.3 52 17.7 0.916*
Special sites involvement      
 Liver 6 4.7 10 3.4 0.519*
 Spleen 28 22.0 19 6.5  < .001*
 Stomach 11 8.6 34 11.6 0.371*
 Intestinal 3 2.3 33 11.2 0.003*
 Waldeyer’ string 26 20.5 71 24.2 0.401*
 Bone 9 7.1 12 4.1 0.196*
Performance status      0.425*
 0–1 115 90.6 272 92.8  
 2–4 12 9.4 21 7.2  
B symptoms present 28 22.0 76 26.0 0.396*
Elevated LDH 59 46.5 135 46.1 0.943*
Ann Arbor stage      0.028*
 I–II 55 43.3 161 54.9  
 III–IV 72 56.7 132 45.1  
Extra-nodal sites ≥ 2 22 17.3 49 16.7 0.880*
IPI score      0.653*
 0–1 103 81.1 232 79.2  
 3–5 24 18.9 61 20.8  
Use of rituximab 60 47.2 143 48.8 0.769*
Response to chemotherapy      0.300
 Complete response 78 61.4 196 66.9  
 Partial response 40 31.5 83 28.3  
 Stable disease 1 0.8 4 1.4  
 Progressive disease 7 5.5 10 3.4  
 Not available 1 0.8 0 0.0  
  1. IPI International Prognostic Index, LDH lactate dehydrogenase
  2. *χ2 test for independence in HBsAg-positive compared with HBsAg-negative patients
  3. Fisher exact test for independence in HBsAg-positive compared with HBsAg-negative patients